Ameliorative Potential Of Cyclopyrrolones (Zopiclone) On Gabaa Receptor In Neuropathic Pain

Abstract

Cyclopyrrolone (Zopiclone) is a nonbenzodiazepine, regulating the GABAA receptor, thus relaxes the nerves and brain. The role of glycinergic and γ-aminobutyric acid (GABA)ergic neurons in this process has been widely described. Benzodiazepine-sensitive GABA_A receptors contain at least one of the following α subunits α1, α2, α3 or α5. Animal studies using inflammatory and neuropathic pain models revealed that α1-sparing (non-sedative) agonists have antihyperalgesic activity without diminishing effectiveness over time. Neuropathic pain is the discomfort brought on by a condition that affects the sensory nerves. Dysesthesia and allodynia can both be brought on by damaged nerves. In the current investigation, Cyclopyrrolones (Zopiclone) decreased allodynia and hyperalgesia brought on by models for Disease-Induced Neuropathy Pain (DINP), Paclitaxel-Induced Neuropathic Pain (PINP), and Chronic Constriction Injury (CCI). Its effect was dose-dependent, and one of its mechanisms of action was probably the sequential activation of spinal neurons at the supraspinal site of action. The current study further supports the likelihood that Cyclopyrrolones (Zopiclone) will be helpful in the management of neuropathic pain, even though further preclinical and clinical research is clearly required.